Sign in
Not yet taking people in United StatesPhase 1

OPT101 in Patients With Community Acquired Pneumonia (CAP) With Sepsis

Key facts

Who runs it
Op-T LLC
Where
Denver, United StatesSee the site
Trial code
Status
Not yet recruiting
Phase
Phase 1
People taking part
26 people, planned
Started
Dec 2025
Planned end
May 2026
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • OPT101
  • Placebo
Record updated
15 September 2025

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 20 criteriaShow less

Who can take part

  • Are able and willing to give signed informed consent (legally authorized representative can provide informed consent if needed)
  • ≥18 years old
  • Patients hospitalized for clinically suspected community acquired pneumonia (CAP), defined as the occurrence of (within 48h from hospital admission) at least 1 of the following signs:; respiratory rate > 30 breaths/min; fever (> 38.0°C or > 100.4° F); leukopenia (≤ 4,000 WBC/mm3 or leukocytosis (≥ 12,000 WBC/mm3); adults ≥ 70 years of age; altered mental status with no other recognized cause; AND at least 1 of the following:; New onset of purulent sputum or change in character of sputum or increased respiratory secretions; New onset or worsening cough, or dyspnea, or tachypnea; Rales or bronchial breath sounds; AND Radiologic imaging (chest x-ray or CT scan) evidence of pulmonary involvement with new and persistent or progressive and persistent infiltrate, consolidation or cavitation AND SpO2 <92% at room air, or PaO2/FiO2 (or SpO2/FiO2) <300; recorded on one episode
  • Need for non-invasive supplemental oxygen (nasal cannula, simple mask, venturi or reservoir cannula/mask or heated high flow nasal cannula oxygen
  • Females of child-bearing potential who are sexually active must not wish to get pregnant within 30 days after the end of the study and must be using at least one of the following reliable methods of contraception:; Hormonal contraception, systemic, implantable, transdermal, or injectable contraceptives for at least 2 months before the screening visit until 30 days after the last OPT101 dose; A non-hormonal intrauterine device [IUD] or female condom with spermicide or contraceptive sponge with spermicide or diaphragm with spermicide or cervical cap with spermicide for at least 2 months before the screening visit until 30 days after the last OPT101 dose; A male sexual partner who agrees to use a male condom with spermicide; A sterile sexual partner

Who cannot take part

  • Treatment with prohibited medication within 5 half-lives, and inability to stop during treatment period
  • Pregnancy:; positive or missing pregnancy test before first drug intake or day 1; pregnant or lactating women; Women of childbearing potential and fertile men who do not agree to use at least one primary form of contraception for the duration of the study
  • Recent or active hepatitis A infection; test positive or have been treated for hepatitis B, hepatitis C, or HIV infection; evidence of active or untreated latent TB; a recent history of recurrent herpes zoster and/or opportunistic infection; and/or taking immunosuppressant medication
  • Allergy to OPT101or any component of OPT101 formulation
  • Complicated CAP-associated conditions, such as fungal pulmonary infection, tuberculosis infection, abscess, empyema, significant bilateral pleural effusion, massive pulmonary embolism
  • Any other condition which the Principal Investigator feels may jeopardize the safety of the patient or the objectives of the study. The Principal Investigator should make this determination in consideration of the patient's medical history and current clinical condition; -
  • QTc ≥ 450 msec on screening ECG
  • Hepatic dysfunction: ALT or AST > 5 ULN; history of chronic hepatic disease (defined with Child-Pugh score ≥ 12)
  • Renal dysfunction: estimated glomerular filtration rate (eGFR) <50 mL/min/1.73 m2, or need for hemodialysis or hemofiltration
  • Current use of >2 immunosuppressive medications or immunosuppression status (AIDS, aplastic anemia, asplenia, systemic chemotherapy within the past 3 months, neutropenia (ANC < local LLN), solid organ or bone marrow transplant recipients)
  • Need for endotracheal intubation and mechanical ventilation or extracorporeal membrane oxygenation (ECMO) at time of study screening
  • Anticipated discharge from the hospital or transfer to another hospital within 48 hours of screening
  • Participation in other interventional clinical trials
  • Current hospital stay >72h
  • Weight is over 250lbs

Where in United States

  • Denver Health and Hospital AuthorityDenver, United StatesContact: Terra Miller, MSN, RNNot yet recruiting

About the trial

What the trial wants to find out

OPT101-100-40 is a multicenter, randomized, placebo-controlled, multiple-ascending-dose, sequential-group, investigator- and participant-blinded, sponsor-unblinded, study of OPT101 vs placebo when administered for up to 4 days to patients admitted to the hospital for treatment of Community Acquired Pneumonia (CAP) with sepsis.

Read full original descriptionShow less

This study will be performed in patients with Community Acquired Pneumonia (CAP) with Sepsis, who are 18 years or older to evaluate the safety and tolerability of OPT101 in a population with elevated levels of pathologic CD40.

The 2 groups in the trial

  • 0.9% Sodium Chloride Injection USPPlacebo, for comparison

    Placebo will be 50mL normal saline (Sodium Chloride), USP sterile solution provided in a 50mL pre-packaged Intravenous (IV) bag.

    Treatment: Placebo

  • OPT101Treatment being tested

    OPT101 (15-mer peptide) will be provided across 2 cohorts at 1.1 (cohort 1) and 2.8 mg/kg (cohort 2) doses . On the day of administration, the product will be diluted in saline to result in 50 mL for intravenous (IV) infusion over 120 minutes.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase 1b Study to Assess the Safety, Tolerability and Pharmacokinetics of OPT101 in Patients With Community Acquired Pneumonia (CAP) With Sepsis
Record updated
15 September 2025